Cited by 76Treatment of Major DepressionElectroconvulsive Therapy StudiesTranscranial Magnetic Stimulation Studies

Ketamine, Sleep, and Depression: Current Status and New Questions

Open access
Duncan, Wallace C., Zarate, Carlos A.·2013·Current Psychiatry Reports

Abstract

Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has well-described rapid antidepressant effects in clinical studies of individuals with treatment-resistant major depressive disorder (MDD). Preclinical studies investigating the effects of ketamine on brain-derived neurotrophic factor (BDNF) and on sleep slow wave activity (SWA) support its use as a prototype for investigating the neuroplastic mechanisms presumably involved in the mechanism of rapidly acting antidepressants. This review discusses human EEG slow wave sleep parameters and plasma BDNF as central and peripheral surrogate markers of plasticity, and their use in assessing ketamine's effects. Acutely, ketamine elevates BDNF levels, as well as early night SWA and high-amplitude slow waves; each of these measures correlates with change in mood in depressed patients who respond to ketamine. The slow wave effects are limited to the first night post-infusion, suggesting that their increase is part of an early cascade of events triggering improved mood. Increased total sleep and decreased waking occur during the first and second night post infusion, suggesting that these measures are associated with the enduring treatment response observed with ketamine.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11920-013-0394-z

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 4

  1. [5]Furey ML Drevets WC Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial Arch Gen Psychiatry 2006 63 1121 9 17015814 PMC3250308
  2. [7]Husain MM Rush AJ Fink M Knapp R Petrides G Rummans T Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report J Clin Psychiatry 2004 65 485 91 15119910
  3. [36]Borbely AA A two process model of sleep regulation Hum Neurobiol 1982 1 195 204 7185792
  4. [59]Kupfer DJ Reynolds CF 3rd Weiss BL Foster FG Lithium carbonate and sleep in affective disorders. Further considerations Arch Gen Psychiatry 1974 30 79 84 4357709

Cited by

Sorted by citations

Authors
Duncan, W. C., & Zarate, C. A.
Affiliations
National Institutes of Health (US)
Corresponding author
Zarate, Carlos A.
Venue
Current Psychiatry Reports
Published
2013-08-16
Volume
15
Issue
9
Pages
394-394
ISSN
  • 1523-3812 (ISSN-L)
  • 1535-1645
OpenAlex
W2092088903
Cited by
76
References
60
Citations by year
2026: 8 · 2025: 5 · 2024: 3 · 2023: 7 · 2022: 4 · 2021: 12 · 2020: 9 · 2019: 4 · 2018: 6 · 2017: 4 · 2016: 7 · 2015: 5 · 2014: 2
FWCI
0.59
Type
journal article
Language
en
Open access
Locations
  • Current Psychiatry Reports (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health
  • National Institute of Mental Health (ZIAMH002857, ZIAMH002927)
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
Keywords
ketamine, major depressive disorder, treatment-resistant depression, rapid-acting antidepressants, NMDA receptor antagonism, brain-derived neurotrophic factor, slow-wave sleep, neuroplasticity, EEG, plasma BDNF, sleep duration, antidepressant response
MeSH terms
Depressive Disorder, Electroencephalography, Humans, Sleep Initiation and Maintenance Disorders, Ketamine, Biomarkers, Excitatory Amino Acid Antagonists, Brain-Derived Neurotrophic Factor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review